COVID-19 vaccine: Russia in touch with Indian firms

RDIF CEO Kirill Dmitriev said that several nations are interested in the production of the vaccine from countries in Latin America, Asia and the Middle East.

Published: 21st August 2020 12:25 AM  |   Last Updated: 22nd August 2020 11:18 AM   |  A+A-

Russian Direct Investment Fund CEO Kirill Dmitriev

Russian Direct Investment Fund CEO Kirill Dmitriev (File photo| AFP)

Express News Service

NEW DELHI:  The Russian government, days after announcing that it was going to start mass vaccination of the world’s first Covid-19 vaccine, is in talks with four Indian vaccine makers for its mass production, which may start as early as October.

Though the Indian government has, so far, been silent on any collaboration with Russia on the vaccine, top authorities in Russia at a press briefing on Thursday announced the proposed tie-ups, which was confirmed by Indian officials.

On August 11, the vaccine named ‘Sputnik V’, endorsed by Russian President Vladimir Putin, has been approved by Russia even as scientists worldwide have expressed scepticism on its safety and efficacy as it has not completed human trials yet, and no data from its early stage trials have been released, so far.
The vaccine has been developed by Gamaleya Research Institute and the Russian defence ministry and has been created using inanimate particles developed based on adenovirus, a class of virus that causes the common cold in primates including humans.

It is set to enter phase 3 trial next week involving 40,000 volunteers, it was also announced on Thursday. 
Kirill Dmitriev, the CEO of the Russian Direct Investment Fund, a government body, which is financing the production of Sputnik V, said at the press briefing that “currently, we are working with 4 partners in India, we believe that they are capable of production of the Gamaleya Institute vaccine.” Russia said while it could produce 500 million doses of the vaccine, it’s looking to churn out 1 billion doses manufactured as many other countries have also shown interest in getting it.

RFID, on its website, has also said it sees “strong global interest in the vaccine and plans to conduct Phase 3 clinical trials in different countries, including Saudi Arabia, UAE, Brazil, India and Philippines, and start mass production in other countries in partnership with local sovereign wealth funds, including India, South Korea and Brazil, as well as, in Saudi Arabia, Turkey and Cuba.” Government officials in India confirmed that Russia has been in talks with the Ministry of External Affairs and some vaccine manufacturers, including Bharat Biotech, for mass production of the vaccine in the country. 


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp